Information Provided By: 
Fly News Breaks for January 11, 2016
AFFX, TMO
Jan 11, 2016 | 08:06 EDT
UBS said the Thermo Fisher (TMO) deal to buy Affymetrix (AFFX) is both strategic and accretive as it allows the company to offer a comprehensive offering in genetic analysis products to the research, clinical, and applied markets. The firm said the deal further supports its buy thesis and said current valuation barely suggests future value creation is being priced in. UBS reiterated its Buy rating and $175 price target on Thermo Fisher shares.
News For TMO;AFFX From the Last 2 Days
TMO
Apr 25, 2024 | 08:51 EDT
Deutsche Bank raised the firm's price target on Thermo Fisher to $610 from $600 and keeps a Buy rating on the shares post the Q1 report. The analyst says a solid operational performance drove a strong start to 2024.
TMO
Apr 25, 2024 | 08:29 EDT
TMO
Apr 25, 2024 | 07:32 EDT
TMO
Apr 25, 2024 | 07:03 EDT
TMO
Apr 25, 2024 | 06:31 EDT
TMO
Apr 25, 2024 | 05:12 EDT
Barclays analyst Luke Sergott raised the firm's price target on Thermo Fisher to $615 from $590 and keeps an Equal Weight rating on the shares. The company reported a beat across the board, says the analyst, who sees the business stabilizing.
TMO
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
TMO
Apr 24, 2024 | 06:11 EDT
TMO
Apr 24, 2024 | 06:09 EDT
TMO
Apr 24, 2024 | 06:02 EDT
